Kamada (KMDA) Stock Price, News & Analysis

Company Overview

Kamada Ltd. is an Israeli biopharmaceutical company focused on the development, manufacturing and commercialization of plasma-derived therapies. The company’s products are designed to treat rare diseases, immune deficiencies and other serious medical conditions, with an emphasis on specialty biologic medicines and immunoglobulin-based treatments.

Kamada’s portfolio includes Glassia, an alpha-1 antitrypsin augmentation therapy for patients with alpha-1 antitrypsin deficiency; KEDRAB, a human rabies immune globulin used for post-exposure prophylaxis; WINRHO SDF, an immune globulin product; and CYTOGAM, a cytomegalovirus immune globulin. The company also develops additional plasma-derived and immunoglobulin therapies through internal research and strategic collaborations.

Founded in 1990, Kamada is headquartered in Rehovot, Israel, and serves healthcare markets in the United States, Israel and other international geographies through direct commercial operations and distribution partnerships. Amir London has served as the company’s chief executive officer, overseeing its expansion as a specialty biopharmaceutical business.

Key Stats

• Today's Range: $7.46 to $7.66
• 50-Day Range: $6.88 to $8.87
• 52-Week Range: $6.55 to $9.35
• Volume: 30,171 shs
• Average Volume: 79,995 shs
• Market Capitalization: $438.97 million
• P/E Ratio: 20.09
• Dividend Yield: 1.70%
• Price Target: $13.50
• Consensus Rating: Buy

Kamada Stock Analysis - MarketRank™

Kamada scored higher than 98% of companies evaluated by MarketBeat, and ranked 6th out of 877 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.1 / 5
• Analyst Rating: Buy

Consensus Rating

Kamada has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on no strong buy ratings, 4 buy ratings, no hold ratings, and no sell ratings.

Upside Potential

Kamada has a consensus price target of $13.50, representing about 77.1% upside from its current price of $7.62.

Amount of Analyst Coverage

Kamada has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 4.4 / 5
• Proj. Earnings Growth: 20.83%

Earnings Growth

Earnings for Kamada are expected to grow by 20.83% in the coming year, from $0.48 to $0.58 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Kamada is 20.06, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 38.83.

Price to Earnings Ratio vs. Sector

The P/E ratio of Kamada is 20.06, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 275.54.

Price to Earnings Growth Ratio

Kamada has a PEG Ratio of 0.66. PEG Ratios below 1 indicate that a company could be undervalued.

Price to Book Value per Share Ratio

Kamada has a P/B Ratio of 1.63. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.57% of the float of Kamada has been sold short.

Short Interest Ratio / Days to Cover

Kamada has a short interest ratio ("days to cover") of 1.82, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Kamada has recently increased by 30.26%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 2.5 / 5
• Dividend Strength: Moderate

Dividend Yield

Kamada pays a meaningful dividend of 1.63%, higher than the bottom 25% of all stocks that pay dividends.

Dividend Growth

Kamada does not have a long track record of dividend growth.

Dividend Coverage

The dividend payout ratio of Kamada is 34.21%. This payout ratio is at a healthy, sustainable level, below 75%.

Dividend Sustainability

Based on earnings estimates, Kamada will have a dividend payout ratio of 22.41% next year. This indicates that Kamada will be able to sustain or increase its dividend.

News and Social Media

• Score: 1.5 / 5
• News Sentiment: 0.47

News Sentiment

Kamada has a news sentiment score of 0.47. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.70 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Kamada this week, compared to 4 articles on an average week.

Search Interest

Only 4 people have searched for KMDA on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.

Company Ownership

• Score: 1.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Kamada insiders have not sold or bought any company stock.

Percentage Held by Insiders

36.10% of the stock of Kamada is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

20.38% of the stock of Kamada is held by institutions.

Company Calendar

• Last Earnings: 8/12/2026
• Record date for 9/17 Dividend: 8/27/2026
• Ex-Dividend for 9/17 Dividend: 8/27/2026
• Dividend Payable: 9/17/2026
• Today: 10/14/2026
• Next Earnings (Estimated): 11/09/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:KMDA
• CIK: 1567529
• Web: www.kamada.com
• Phone: (728) 940-6472
• Fax: 972-8940-6473
• Employees: 462
• Year Founded: 1990

Price Target and Rating

• Average Price Target for Kamada: $13.50
• High Price Target: $15.00
• Low Price Target: $11.00
• Potential Upside/Downside: +76.9%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 4 Analysts

Profitability

• EPS (Trailing Twelve Months): $0.38
• Trailing P/E Ratio: 20.09
• Forward P/E Ratio: 15.90
• P/E Growth: 0.66
• Net Income: $20.20 million
• Net Margins: 11.60%
• Pretax Margin: 13.91%
• Return on Equity: 8.37%
• Return on Assets: 5.85%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 4.06
• Quick Ratio: 2.29

Sales & Book Value

• Annual Sales: $180.46 million
• Price / Sales: 2.43
• Cash Flow: $0.59 per share
• Price / Cash Flow: 12.84
• Book Value: $4.68 per share
• Price / Book: 1.63

Miscellaneous

• Outstanding Shares: 57,510,000
• Free Float: 36,746,000
• Market Cap: $438.97 million
• Optionable: Optionable
• Beta: 0.89